A single-session consultation to enhance mental health treatment engagement in patients with comorbid physical and mental problems: study protocol for a pilot randomized controlled trial Authors: Jacqueline L Tilley, Jia Xin Choon, Sakura Ito, Behram A Khan, Konstadina Griva, Shannon Ang, Luke Kang-kwong, Jessica L Schleider Published: 2026 ABSTRACT AbstractBackgroundIndividuals with chronic physical diseases are at elevated risk of developing mental health disorders. Comorbid chronic physical disease and mental health problems (CPDMHP) are associated with substantial societal and healthcare costs. Although enhancing mental healthcare for this population can improve outcomes, efforts to increase service engagement have had limited success. This study evaluates a Solution-Focused Single-Session Consultation (SF-SSC) as a brief, innovative approach to addressing structural and attitudinal barriers to treatment engagement.Methods/designThe study will comprise two phases: Phase 1 will consist of a prospective cross-sectional study of patients in an outpatient community health setting in Singapore. Participants will complete measures of their sociodemographic characteristics, physical and mental health status (e.g., current and past physical and mental health conditions, and service utilization), and psychosocial indicators (e.g., life satisfaction, hope, readiness for change). Phase 2 will involve a two-arm randomized controlled pilot trial that evaluates the feasibility, acceptability, and preliminary effectiveness of the SF-SSC compared with a single session of supportive therapy (SPT). Up to 60 participants from Phase 1 with elevated depression or anxiety symptoms (PHQ-9 or GAD-7 scores ≥ 5) will be randomized to receive the SF-SSC or SPT intervention. Phase 1 analyses will examine the associations among sociodemographic characteristics, physical and mental health factors, and psychological and psychosocial outcomes. The primary outcomes of Phase 2 will be the feasibility and acceptability of the SF-SSC, assessed by the completion of SF-SSC action plans (with a predefined ≥ 70% threshold) and participant-reported usefulness and satisfaction. The primary clinical/process outcome will be treatment engagement, operationalized as the willingness to be referred and attendance at a subsequent appointment. Exploratory secondary outcomes will include psychosocial constructs that are hypothesized to underlie intervention effects, such as hope, perceived agency, readiness to change, and life satisfaction. Given the pilot nature of the trial, clinical and psychosocial findings will be interpreted as preliminary indicators of potential benefit rather than confirmatory evidence of efficacy.DiscussionFindings from this study will inform future trials examining the large-scale and long-term impact of the intervention. The study will also inform the design of scalable approaches that can be integrated into existing mental healthcare systems to improve mental health service uptake and engagement among individuals with CPDMHP.Trial registrationThe trial was retrospectively registered at Clinicaltrials.gov [NCT07116655] on August 11, 2025.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40814-026-01870-2.Keywords: Mental health, Psychosocial intervention, Chronic disease Introduction Chronic physical diseases are a major public health concern and a leading cause of global morbidity and mortality, with increasing prevalence and associated healthcare costs [1]. Yet, despite their widespread impact, the psychosocial effects of these chronic health conditions are often neglected [2]. Studies show that the global pooled prevalence of mental disorders among individuals with chronic physical diseases is 36.6% [3]. This high prevalence is thought to reflect the combined effects of reduced quality of life, loss of autonomy, and the psychological burden of chronic disease [4, 5], which increases vulnerability to stress, anxiety, and depression, as well as the risk of developing mental health problems relative to individuals without chronic conditions [6, 7]. Moreover, the relation between chronic physical diseases and mental health symptoms may be bidirectional, with mental health problems potentially exacerbating physical health symptoms, complicating disease management, and increasing overall health risks [8]. Comorbid chronic physical disease and mental health problems (CPDMHP) are associated with significant societal costs, including greater disability and symptom burden [9], reduced quality and length of life [10–12], and decreased economic productivity [13]. These patients also place considerable demands on the healthcare system as they require more intensive clinical management (e.g., increased hospitalizations, more frequent outpatient visits) than those without such comorbidities [14, 15]. Enhancing mental healthcare for individuals with comorbid CPDMHP has the potential to improve overall patient outcomes [16–18]. Given trends indicating a rising prevalence of comorbid CPDMHP over time [9], targeted efforts are needed to mitigate these burdens and support the sustainability and efficiency of healthcare systems. To guide such efforts, it is essential to gain a clearer understanding of the prevalence of mental health symptoms and the psychosocial factors that influence engagement with mental health services among patients with comorbid CPDMHP within their specific clinical contexts. A significant challenge to the delivery of effective healthcare for individuals with comorbid CPDMHP is the underutilization of mental health services [19], which is largely attributed to structural and attitudinal barriers to treatment [17, 20]. Structural barriers refer to systemic impediments to treatment, including the financial cost of care, transportation difficulties, inflexible scheduling, and the time demands associated with traditional treatment modalities. Attitudinal barriers involve individual-level perceptions and beliefs that deter engagement, such as mental health-related stigma (e.g., concerns about social judgment associated with having a mental health problem or seeking treatment), a desire for agency and self-help (e.g., the belief that one should cope independently or does not require professional help), and low treatment expectancy (e.g., the belief that symptoms will resolve without formal intervention). Existing interventions have primarily targeted attitudinal barriers through psychoeducation and awareness efforts, with comparatively little attention to other psychological factors such as perceived agency and treatment expectancy [21]. Addressing these attitudinal barriers more comprehensively is critical to improving service engagement and equity in care for individuals with comorbid CPDMHP [22, 23]. One potentially useful framework for addressing these attitudinal barriers is hope theory. Hope theory conceptualizes hope as comprising two inter-related components: agency (goal-directed motivation) and pathways thinking (the perceived ability to generate routes toward desired goals). Patients often enter psychotherapy with diminished hope and uncertainty about the possibility of change, and fostering hope is often regarded as a core common factor that underlies both treatment engagement and therapeutic change. Research suggests that hope is also malleable: brief interventions targeting hope and goal-directed action have been shown to increase agency, reduce hopelessness, and reduce symptoms of depression and anxiety across community and clinical populations [24–27]. Moreover, “strengthening early hope” has been identified as one of six evidence-based strategies for reducing premature termination from psychotherapy [28]. Together, these findings suggest that instilling hope and agency may strengthen clients’ motivation to initiate and persist with treatment despite barriers. The proposed intervention, the SF-SSC, is an adaptable, single-session consultation that draws on the core principles of Solution-Focused Brief Therapy (SFBT), an evidence-based psychosocial intervention [29]. Developed as a 30- to 90-min, single-encounter protocol, the SF-SSC is designed to enhance an individual’s sense of agency and hope by identifying and leveraging their existing internal assets and resources (e.g., coping strategies, social supports) and empowering them to take the next small step toward addressing a current problem [24, 25, 30]. As such, the intervention is broadly applicable across the lifespan, irrespective of problem type and severity. Its strength-based approach contrasts with traditional clinical interventions, which typically emphasize the identification and remediation of an individual’s deficiencies or impairments (i.e., a deficit-based approach). Furthermore, the intervention is designed to be scalable. Prior SF-SSC trials suggest that clinicians with varying levels of training, including master’s-level trainees, doctoral trainees, and postdoctoral clinicians, can be trained to deliver the intervention with acceptable fidelity following a structured 90-min training session combined with regular supervision [24, 25]. Because the SF-SSC directly targets two core transdiagnostic mechanisms of psychological change—hope and agency [24, 25]—it may help reshape maladaptive attitudinal belief systems related to hopelessness and perceived agency that discourage help-seeking (e.g., “Things won’t get better no matter what I do”) [31]. Moreover, its strength-based orientation makes it particularly well-suited to addressing a common stigma-related barrier to seeking care: the belief that help-seeking is a sign of weakness or personal failure (e.g., “I should be able to handle this on my own”). Emerging evidence also suggests that SF-SSC can enhance individuals’ readiness for change [25], thus potentially increasing their motivation and willingness to engage with mental health services. Collectively, these features position the SF-SSC as a potential adjunct to existing care models, with the capacity to enhance mental health service utilization and engagement. Furthermore, prior research indicates that interventions such as Motivational Interviewing (MI)—which share core principles with SFBT approaches, including collaboration, respect for autonomy, and eliciting clients’ intrinsic motivation for change [32]—can enhance treatment engagement, including among individuals with chronic diseases [33, 34]. These findings suggest that the common active ingredients underlying MI may similarly promote engagement in the SF-SSC. However, the SF-SSC may be particularly well-suited for patients with comorbid physical and mental health conditions, as it does not require individuals to acknowledge a “problem” or express readiness to change. In contrast, MI is most effective when patients recognize and experience ambivalence about change [35]. The SF-SSC’s future-oriented, strengths-based approach facilitates engagement even when readiness or insight is limited, by focusing on achievable steps and amplifying existing resources rather than exploring barriers or deficits. The primary aim of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of the SF-SSC in enhancing mental health treatment uptake and engagement among patients with comorbid CPDMHP in an outpatient community health setting in Singapore. In addition, the study will explore the prevalence and severity of comorbid mental health problems, as well as the psychosocial factors associated with mental health service engagement in this population, to inform future intervention efforts. Objectives The study objectives are organized as follows. For Phase 1, the objectives are descriptive and exploratory, with the aim of characterizing the target population. For Phase 2, feasibility and acceptability are the primary objectives, treatment engagement is the primary preliminary clinical/process outcome, and psychosocial constructs are exploratory mechanistic outcomes. Consistent with the pilot nature of the study, hypotheses regarding intervention effects are considered exploratory and are intended to inform the design and refinement of a larger-scale confirmatory trial, rather than to provide definitive evidence of efficacy. Phase 1 objectives: Characterizing the target population Objective 1: To determine the prevalence of depressive and anxiety symptoms among patients in an outpatient community health setting in Singapore.oThis objective is exploratory in nature; no specific hypothesis is proposed. Objective 1: To determine the prevalence of depressive and anxiety symptoms among patients in an outpatient community health setting in Singapore.oThis objective is exploratory in nature; no specific hypothesis is proposed. oThis objective is exploratory in nature; no specific hypothesis is proposed. This objective is exploratory in nature; no specific hypothesis is proposed. Objective 2: To examine associations among sociodemographic characteristics, physical and mental health status (e.g., current health status, physical and mental health history, service utilization), and psychological (e.g., depression, anxiety) and psychosocial outcomes (e.g., life satisfaction, hope, readiness for change).oThis objective is also exploratory in nature; no specific hypothesis is proposed. Objective 2: To examine associations among sociodemographic characteristics, physical and mental health status (e.g., current health status, physical and mental health history, service utilization), and psychological (e.g., depression, anxiety) and psychosocial outcomes (e.g., life satisfaction, hope, readiness for change).oThis objective is also exploratory in nature; no specific hypothesis is proposed. oThis objective is also exploratory in nature; no specific hypothesis is proposed. This objective is also exploratory in nature; no specific hypothesis is proposed. Phase 2 primary objectives: Feasibility and acceptability of the SF-SSC Objective 3: To evaluate the feasibility of delivering the SF-SSC, defined as ≥ 70% completion of SF-SSC action plans across eligible participants. This threshold is consistent with prior SSC pilot trials [24, 25], which used 70–80% completion benchmarks to indicate adequate intervention fidelity and feasibility.oHypothesis 3: The interventionists will complete ≥ 70% sessions of the SF-SSC sessions, as documented by the proportion of completed Action Plans. Objective 3: To evaluate the feasibility of delivering the SF-SSC, defined as ≥ 70% completion of SF-SSC action plans across eligible participants. This threshold is consistent with prior SSC pilot trials [24, 25], which used 70–80% completion benchmarks to indicate adequate intervention fidelity and feasibility.oHypothesis 3: The interventionists will complete ≥ 70% sessions of the SF-SSC sessions, as documented by the proportion of completed Action Plans. oHypothesis 3: The interventionists will complete ≥ 70% sessions of the SF-SSC sessions, as documented by the proportion of completed Action Plans. Hypothesis 3: The interventionists will complete ≥ 70% sessions of the SF-SSC sessions, as documented by the proportion of completed Action Plans. Objective 4: To assess the acceptability of the SF-SSC relative to a single-session of supportive therapy (SPT), as indicated by participant-reported satisfaction and perceived usefulness immediately post-intervention.oHypothesis 4 (exploratory): Participants in the SF-SSC group are expected to report higher perceived usefulness in addressing their clinical needs and greater satisfaction with the session’s outcomes compared to participants in the SPT group. Objective 4: To assess the acceptability of the SF-SSC relative to a single-session of supportive therapy (SPT), as indicated by participant-reported satisfaction and perceived usefulness immediately post-intervention.oHypothesis 4 (exploratory): Participants in the SF-SSC group are expected to report higher perceived usefulness in addressing their clinical needs and greater satisfaction with the session’s outcomes compared to participants in the SPT group. oHypothesis 4 (exploratory): Participants in the SF-SSC group are expected to report higher perceived usefulness in addressing their clinical needs and greater satisfaction with the session’s outcomes compared to participants in the SPT group. Hypothesis 4 (exploratory): Participants in the SF-SSC group are expected to report higher perceived usefulness in addressing their clinical needs and greater satisfaction with the session’s outcomes compared to participants in the SPT group. Phase 2 primary clinical/process outcomes: Treatment engagement Objective 5: To evaluate the preliminary effectiveness of SF-SSC’s effects on treatment engagement, operationalized as (1) the willingness to be referred to mental health services or to schedule a follow-up session immediately post-intervention, and (2) attendance at the scheduled appointment within 2 weeks.oHypothesis 5 (exploratory): Participants in the SF-SSC group are expected to show a higher likelihood of expressing interest in a referral or scheduling a follow-up session, as well as attending the subsequent session, relative to participants in SPT. This hypothesis is informed by prior evidence [24] suggesting that interventions that target hope, agency, and readiness for change may strengthen a client’s motivation to initiate and engage with treatment [28]. Objective 5: To evaluate the preliminary effectiveness of SF-SSC’s effects on treatment engagement, operationalized as (1) the willingness to be referred to mental health services or to schedule a follow-up session immediately post-intervention, and (2) attendance at the scheduled appointment within 2 weeks.oHypothesis 5 (exploratory): Participants in the SF-SSC group are expected to show a higher likelihood of expressing interest in a referral or scheduling a follow-up session, as well as attending the subsequent session, relative to participants in SPT. This hypothesis is informed by prior evidence [24] suggesting that interventions that target hope, agency, and readiness for change may strengthen a client’s motivation to initiate and engage with treatment [28]. oHypothesis 5 (exploratory): Participants in the SF-SSC group are expected to show a higher likelihood of expressing interest in a referral or scheduling a follow-up session, as well as attending the subsequent session, relative to participants in SPT. This hypothesis is informed by prior evidence [24] suggesting that interventions that target hope, agency, and readiness for change may strengthen a client’s motivation to initiate and engage with treatment [28]. Hypothesis 5 (exploratory): Participants in the SF-SSC group are expected to show a higher likelihood of expressing interest in a referral or scheduling a follow-up session, as well as attending the subsequent session, relative to participants in SPT. This hypothesis is informed by prior evidence [24] suggesting that interventions that target hope, agency, and readiness for change may strengthen a client’s motivation to initiate and engage with treatment [28]. Phase 2 exploratory mechanistic outcomes: Psychosocial constructs Objective 6: to explore whether psychosocial constructs hypothesized to function as mechanisms underlying intervention effects (e.g., hope, agency, readiness to change) demonstrate greater pre-to-post and pre-to-follow-up improvements in the SF-SCC condition relative to SPT.oHypothesis 6 (exploratory): consistent with prior SF-SSC trials demonstrating positive pre-post effects on agency and hopelessness [24, 25], we anticipate trends towards greater improvement in hope, agency, and readiness for change among SF-SSC participants relative to SPT participants at both post-intervention and 2-week follow-up. Objective 6: to explore whether psychosocial constructs hypothesized to function as mechanisms underlying intervention effects (e.g., hope, agency, readiness to change) demonstrate greater pre-to-post and pre-to-follow-up improvements in the SF-SCC condition relative to SPT.oHypothesis 6 (exploratory): consistent with prior SF-SSC trials demonstrating positive pre-post effects on agency and hopelessness [24, 25], we anticipate trends towards greater improvement in hope, agency, and readiness for change among SF-SSC participants relative to SPT participants at both post-intervention and 2-week follow-up. oHypothesis 6 (exploratory): consistent with prior SF-SSC trials demonstrating positive pre-post effects on agency and hopelessness [24, 25], we anticipate trends towards greater improvement in hope, agency, and readiness for change among SF-SSC participants relative to SPT participants at both post-intervention and 2-week follow-up. Hypothesis 6 (exploratory): consistent with prior SF-SSC trials demonstrating positive pre-post effects on agency and hopelessness [24, 25], we anticipate trends towards greater improvement in hope, agency, and readiness for change among SF-SSC participants relative to SPT participants at both post-intervention and 2-week follow-up. Methods and analysis Study design The study will use a two-part design comprising Phase 1, a prospective cross-sectional study, and Phase 2, a two-arm, parallel pilot randomized controlled (RCT) to evaluate the effect of the SF-SSC on engagement with mental health services (see Fig. 1 for the study flowchart). Phase 1 was designed primarily to: (a) screen and identify participants eligible for Phase 2, and (b) characterize the prevalence of depressive and anxiety symptoms, as well as the psychosocial profile, of patients with chronic physical disease in this outpatient community-health setting. Although Phase 1 provides important contextual information about the recruitment pool, it was not intended to directly inform the intervention content or analytic models in Phase 2 beyond participant identification. Flowchart of the study design for Phase 2 The study will be conducted in accordance with the CONSORT 2010 Statement: Extension to Randomized Pilot and Feasibility Trials [36] and will adhere to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [37] reporting guidelines and checklist (Supplementary Material 1). This trial was retrospectively registered on ClinicalTrials.gov (NCT07116655) on 11 August 2025. We acknowledge that retrospective registration may limit transparency regarding pre-specification of design and analytic decisions. However, the core study design—including inclusion/exclusion criteria, intervention and comparator procedures, primary feasibility and acceptability outcomes, and the planned outcome assessment schedule—was specified in the study protocol approved by the Nanyang Technological University Institutional Review Board (NTU IRB; IRB-2024-777) prior to participant recruitment. Patients and public involvement Patients and the public will not be involved in the design of this study. Their involvement will be limited to participation in the interventions and outcome assessments. There are no plans for patient or public involvement in the reporting or dissemination of the study findings. Subjects and setting The study will be conducted at an outpatient community health setting focused on serving patients with chronic physical diseases in Singapore (i.e., outpatient community kidney dialysis center). All patients currently receiving care will be approached by the research team. Potential participants will receive detailed information about the study, and those who express interest will undergo screening to determine eligibility. Inclusion criteria for Phase 1 are (1) currently receiving treatment at an outpatient community health setting; (2) having a history of one or more chronic physical diseases, as defined by the Ministry of Health (Singapore) Chronic Disease Management Programme Guidelines [38]; (3) aged 21 years and above; and (4) conversant in English. Patients with an intellectual disability, pervasive developmental disorder, or a history of psychosis—as identified through information provided by clinical staff at the participating site familiar with the patients’ medical histories and clinical records—will be excluded. Additional criteria for Phase 2 are (1) exhibiting at least mild symptoms of depression or anxiety (i.e., score of ≥ 5 on either the Patient Health Questionnaire-9 (PHQ-9) [39] or Generalized Anxiety Disorder-7 (GAD-7) [40]; and (2) not currently engaged in formal mental health services (e.g., specialist outpatient psychological or psychiatric care, community-based counseling services). Measures Data collection will include four outcome assessments: screening/baseline, pre-intervention, post-intervention, and follow-up. Data will be obtained primarily through self-report questionnaires administered via Qualtrics (Qualtrics LLC, Provo, UT, USA). Sociodemographic characteristics Participants will be asked to provide information on their age (in years), gender (male, female, other), marital status (single, never married, married or domestic partnership, widowed, divorced, separated), ethnicity (Chinese, Malay, Indian, mixed race, other), country of birth (Singapore, other), housing type (1 or 2 room HDB flat, 3 room HDB flat, 4 room HDB flat, 5 room HDB flat/Executive flat, private condominium/apartment, landed property/house), highest education level (primary level or below, secondary level, Institute of Technical Education certificate, Polytechnic certificate, GCE A Levels/IB diploma, university degree, postgraduate degree, others), and subjective social status (MacArthur Scale of Subjective Social Status) [41]. Participants will be asked to provide information on their age (in years), gender (male, female, other), marital status (single, never married, married or domestic partnership, widowed, divorced, separated), ethnicity (Chinese, Malay, Indian, mixed race, other), country of birth (Singapore, other), housing type (1 or 2 room HDB flat, 3 room HDB flat, 4 room HDB flat, 5 room HDB flat/Executive flat, private condominium/apartment, landed property/house), highest education level (primary level or below, secondary level, Institute of Technical Education certificate, Polytechnic certificate, GCE A Levels/IB diploma, university degree, postgraduate degree, others), and subjective social status (MacArthur Scale of Subjective Social Status) [41]. Physical and mental health status Physical health status will be evaluated using a single-item self-report measure (“In general, how would you rate your current health?”) rated on a 5-point Likert scale, with higher scores indicating better perceived health. Additional information on physical health (e.g., type of diagnosed chronic conditions) will also be collected. Physical health status will be evaluated using a single-item self-report measure (“In general, how would you rate your current health?”) rated on a 5-point Likert scale, with higher scores indicating better perceived health. Additional information on physical health (e.g., type of diagnosed chronic conditions) will also be collected. Mental health status will be assessed using the Patient Health Questionnaire-9 (PHQ-9) [39] and the Generalized Anxiety Disorder-7 (GAD-7) [40]. The PHQ-9 is a 9-item self-report scale that measures depressive symptoms based on DSM-IV criteria for major depressive disorder, while the GAD-7 is a 7-item self-report scale that measures worry and anxiety symptoms. Both instruments are rated on a 4-point Likert scale, with higher scores indicating greater symptom severity. Scores of 5 and above on either scale reflect mild symptom elevation [39, 40]. Information on participants’ current or past use of mental health support will also be documented. Mental health status will be assessed using the Patient Health Questionnaire-9 (PHQ-9) [39] and the Generalized Anxiety Disorder-7 (GAD-7) [40]. The PHQ-9 is a 9-item self-report scale that measures depressive symptoms based on DSM-IV criteria for major depressive disorder, while the GAD-7 is a 7-item self-report scale that measures worry and anxiety symptoms. Both instruments are rated on a 4-point Likert scale, with higher scores indicating greater symptom severity. Scores of 5 and above on either scale reflect mild symptom elevation [39, 40]. Information on participants’ current or past use of mental health support will also be documented. Psychosocial and engagement indicators Agency and hope will be measured with the State Hope Scale (SHS) [42] and Beck Hopelessness Scale-4 (BHS-4) [43], respectively. The SHS is a 6-item self-report measure of agentic, goal-directed thinking. Items are scored on an 8-point Likert scale from 1 (definitely false) to 8 (definitely true), with higher scores reflecting greater perceived agency. The BHS-4 is a 4-item self-report measure that assesses hopelessness. Items are scored on a 4-point scale (0–3), with higher scores reflecting greater hopelessness. Agency and hope will be measured with the State Hope Scale (SHS) [42] and Beck Hopelessness Scale-4 (BHS-4) [43], respectively. The SHS is a 6-item self-report measure of agentic, goal-directed thinking. Items are scored on an 8-point Likert scale from 1 (definitely false) to 8 (definitely true), with higher scores reflecting greater perceived agency. The BHS-4 is a 4-item self-report measure that assesses hopelessness. Items are scored on a 4-point scale (0–3), with higher scores reflecting greater hopelessness. Readiness for change will be assessed using the Readiness Ruler [44], a 2-item self-report measure, with items scored on a 10-point scale (0–10). Higher scores indicate greater perceived importance of making changes and higher confidence in one’s ability to carry them out. Readiness for change will be assessed using the Readiness Ruler [44], a 2-item self-report measure, with items scored on a 10-point scale (0–10). Higher scores indicate greater perceived importance of making changes and higher confidence in one’s ability to carry them out. Satisfaction with life will be evaluated using a single-item self-report measure [45] (i.e. “In general, how satisfied are you with your life?”) scored on a 5-point Likert Scale, with higher scores reflecting higher satisfaction with life. Satisfaction with life will be evaluated using a single-item self-report measure [45] (i.e. “In general, how satisfied are you with your life?”) scored on a 5-point Likert Scale, with higher scores reflecting higher satisfaction with life. Uptake and engagement will be assessed by participants’ willingness to be referred to mental health services (or to attend a second follow-up session with the interventionist) after the intervention, as well as their attendance at the scheduled session, as reported in the 2-week follow-up survey. Uptake and engagement will be assessed by participants’ willingness to be referred to mental health services (or to attend a second follow-up session with the interventionist) after the intervention, as well as their attendance at the scheduled session, as reported in the 2-week follow-up survey. Feasibility and acceptability of SF-SSC Feasibility will be measured by the number of completed SF-SSC action plans. In addition, interventionists will provide qualitative feedback on the ease of implementing the intervention and reasons for any non-completion. Feasibility will be measured by the number of completed SF-SSC action plans. In addition, interventionists will provide qualitative feedback on the ease of implementing the intervention and reasons for any non-completion. Acceptability will be evaluated by asking participants to rate a series of statements on a 1 (not at all) −5 (very much) scale about how helpful they found the SF-SSC in addressing their concerns immediately post-intervention [24]. A total mean score will be calculated, with higher mean scores indicating higher perceived usefulness of the SF-SSC. Participants will also be invited to provide qualitative feedback on ways to improve the intervention’s acceptability. Acceptability will be evaluated by asking participants to rate a series of statements on a 1 (not at all) −5 (very much) scale about how helpful they found the SF-SSC in addressing their concerns immediately post-intervention [24]. A total mean score will be calculated, with higher mean scores indicating higher perceived usefulness of the SF-SSC. Participants will also be invited to provide qualitative feedback on ways to improve the intervention’s acceptability. Intervention fidelity will be assessed using a fidelity checklist completed by session observers (Supplementary Material 2). Observers will indicate the extent to which the interventionists demonstrated specific behaviours or posed particular questions during the session. Twelve items will be rated on a 3-point Likert scale (0 = not at all; 2 = yes, quite a bit) to evaluate adherence to the intervention protocol. Even-numbered items correspond to core SFBT principles, whereas odd-numbered items reflect general therapeutic principles and best practices. A total mean score will be calculated for the even-numbered items, with higher scores indicating greater fidelity to SFBT. Intervention fidelity will be assessed using a fidelity checklist completed by session observers (Supplementary Material 2). Observers will indicate the extent to which the interventionists demonstrated specific behaviours or posed particular questions during the session. Twelve items will be rated on a 3-point Likert scale (0 = not at all; 2 = yes, quite a bit) to evaluate adherence to the intervention protocol. Even-numbered items correspond to core SFBT principles, whereas odd-numbered items reflect general therapeutic principles and best practices. A total mean score will be calculated for the even-numbered items, with higher scores indicating greater fidelity to SFBT. Procedure Participants enrolled in the study will follow the study flow and outcome assessments outlined in Fig. 2. The study comprises two phases:Pphase 1, a cross-sectional study, followed by Phase 2, a pilot RCT. Study procedure: Schedule of enrollment, interventions and assessments, reflecting the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure Phase 1 Written informed consent will be obtained from participants prior to enrolment. Participants will then complete an English-language questionnaire assessing sociodemographic characteristics, physical and mental health status, and life satisfaction. The questionnaire may be completed independently online or administered verbally by the research team. Participants will receive a $5 retail voucher for their time. This questionnaire will serve as both the eligibility screener and the baseline assessment for Phase 2. Phase 2 Phase 1 participants who score ≥ 5 on either the PHQ-9 or GAD-7 and are not currently receiving formal mental health services will be invited to participate in Phase 2. They will be asked whether they would like a “brief consultation session” with an interventionist, given their elevated scores. Those who agree will be randomly assigned, in a 1:1 ratio, to either the intervention group (SF-SSC) or the comparison group (SPT). Each session will be observed by a research assistant present in the same room as the interventionist and participant. Participants will be informed during the consent process that a research assistant will be present for session documentation purposes and consent for observation will be obtained as part of study enrolment. Efforts will be made to minimize disruption to the session (e.g., observer will be seated outside the immediate interaction space and will not participate in the conversation). Randomization and allocation will be generated using the Clinical Trial Randomization Tool (https://ctrandomization.cancer.gov/tool/). Allocation concealment will be maintained by assigning each participant an anonymous code linked to the randomization sequence. Participants will not be informed of their group assignment or that the two conditions differ. Although participants cannot be blinded to receiving an intervention, they will remain unaware of condition labels and will not be told which intervention types they received. Research assistants conducting fidelity observations and outcome assessments will also be blinded to group allocation throughout the study, and the data analyst will be blinded until completion of the primary feasibility analyses. Before the intervention, participants will rate their levels of hope, perceived agency, and readiness for change. Each intervention session will last approximately 45–60 min. After the session, participants will be asked whether they would like (1) a referral to mental health services, or (2) to schedule a second session with the interventionist at least 2 weeks later (i.e., after the 2-week follow-up survey). They will also re-rate their hope, perceived agency, and readiness for change, and provide feedback on the session’s usefulness and acceptability. Two weeks after the intervention, participants will be contacted by the research team to complete a follow-up survey by phone or in person. This survey will assess current physical and mental health status and psychosocial indicators. Participants will receive a $30 retail voucher for completing the intervention and a $5 retail voucher for completing the follow-up survey. Intervention group (SF-SSC) Participants in the intervention group will receive the SF-SSC, delivered by a trained interventionist. At the outset, the interventionist will set expectations by explaining that the session provides brief, short-term support. Participants will also be affirmed for their willingness to engage and oriented to the session structure. During the session, the interventionist will work with participants to (1) identify a specific, modifiable issue they are currently facing; (2) use the “miracle question” and a scaling exercise to envision their ideal outcome and assess their current distance from it; (3) determine the “smallest possible step” they can take towards that outcome; and (4) develop a personalized action plan that leverages their existing strengths and resources to begin addressing the problem. At the end of the session, the interventionist will write a personalized note on the action plan, highlighting the participant’s strengths and expressing confidence in their ability to follow through. Participants will receive a copy of the plan at the end of the session. Interventionists will hold at least a bachelor’s degree in psychology, counseling, or a related field, and will have prior training in basic counseling skills as well as experience working with vulnerable populations in clinical or community settings. To ensure treatment fidelity, interventionists will complete standardized training in SF-SSC conducted by the principal investigator (JLT) prior to participant contact. The training will comprise (i) review of the open-access SF-SSC protocol and accompanying materials [46]; (ii) approximately 90 min of structured online instruction covering core components of the SF-SSC, including the action plan (Supplementary Material 3); and (iii) submission of recorded role-plays demonstrating delivery of both SF-SSC and SPT interventions. Role-plays will be reviewed by the principal investigator using the fidelity checklist, and interventionists will be required to demonstrate adequate competence before delivering either intervention to study participants. Regular supervision by the principal investigator will be provided throughout the study to support fidelity and address any implementation challenges. Comparison group (SPT) Participants in the comparison group (SPT) will receive a single session of supportive therapy intervention delivered by trained interventionists drawn from the same provider pool as the SF-SSC condition. The SPT is non-manualized and follows a non-directive framework focused on (i) rapport building; (ii) open exploration of participant-led concerns; and (iii) reflective listening, validation, empathy, and reassurance. The SPT condition is designed as an active control to account for non-specific therapeutic factors, such as therapist attention, empathy, alliance, and time matched to the SF-SSC condition, which will allow for the isolation of the specific effects of the solution-focused components. Fidelity to the SPT framework will be monitored using the same observer-rated checklist, in which odd-numbered items assess therapeutic elements common to both conditions, and even-numbered items assess SF-SSC-specific components that should be absent from SPT sessions. Participant safety and confidentiality Participants may experience some emotional discomfort when discussing their emotional concerns, stressful life experiences, and other personal matters during the assessment or intervention sessions; however, such discomfort is expected to be temporary. To minimize distress, participants will be informed that they may decline to answer any questions that cause discomfort. If a participant exhibits significant distress or inadvertently discloses sensitive information, including suicidal ideation, sexual harassment, or abuse, the research team will follow two NTU IRB-approved Standard Operating Procedures (SOPs) addressing (1) acute participant distress and (2) inadvertent disclosure of sensitive or reportable information. These SOPs outline procedures for immediate response, risk assessment, referral to appropriate support services, documentation, and escalation to clinical staff, the Principal Investigator, and/or NTU IRB, where appropriate, to ensure participant safety, ethical management, and compliance with institutional and legal requirements. Information regarding these potential risks and corresponding management procedures will be included in the informed consent forms and discussed with participants during the recruitment process. To protect confidentiality, each participant will be assigned a unique study ID at enrolment. All study data will be linked only to this ID and stored in password-protected files accessible exclusively to the research team. Signed consent forms will be stored separately in a locked cabinet. No audio or video recordings of intervention sessions will be collected. Sample size Because the sample size is limited by the number of individuals receiving care at the outpatient community health setting, Phase 1 recruitment will follow a consecutive sampling approach. All eligible participants during the study period will be invited to participate. Thus, the final sample size is determined by patient volume at the setting rather than a priori statistical power considerations. This approach is appropriate given the study’s exploratory nature and the constraints on feasibility in the real-world service setting. For Phase 2, we will aim to recruit up to 60 participants with comorbid CPDMHP, randomized 1:1 to the SF-SSC or SPT condition. Consistent with the pilot and feasibility framing of this study, the trial will not be powered to detect a definitive between-group effect on the primary clinical/process outcome of treatment engagement. Prior SF-SSC studies have reported medium-to-large pre-post effects on psychosocial outcomes [24, 25], including agency, hopelessness, distress, and readiness for change (dz = 0.40–1.43). However, effects in the proposed trial are expected to be smaller because of the greater clinical complexity associated with comorbid CPDMHP, the use of an active comparison group rather than waitlist control, and the focus on a behavioral engagement outcome. For transparency, an illustrative power calculation was conducted using G*Power 3.1.9.7 [47] for the primary clinical/process outcome of treatment engagement. Assuming a small between-group difference in engagement rates (50% vs. 60%; Cohen’s ≈ 0.20), a two-sided α = 0.05, 1:1 allocation, and up to 20% attrition from the planned sample of 60 participants, the retained sample (n = 48; 24 per group) would provide approximately 11% power to detect a between-group difference. The trial is therefore not intended to provide confirmatory evidence of intervention efficacy. The target sample size was instead determined pragmatically based on anticipated patient volume during the recruitment period and recommendations for pilot randomized trials. Specifically, when small standardized effects are anticipated, Whitehead et al.’s recommend approximately 25 participants per arm as a pilot sample size to inform a subsequent definitive trial [48]. The primary purpose of Phase 2 will be to evaluate feasibility and acceptability and to generate preliminary estimates of effect sizes and variability to inform the design of a future fully powered trial. Data analysis plan Phase 1 (prospective cross-sectional study) Participant data will be used to describe the sociodemographic characteristics, physical and mental health status (e.g., current and past physical health and mental health , service engagement), and psychosocial indicators (e.g., agency, hope, life satisfaction) of patients with chronic physical diseases receiving care at an outpatient community health setting in Singapore. These data will be summarized using frequencies, means, and standard deviations. Bivariate analyses (e.g., t-tests, chi-square tests, correlations) and regression models will be performed to examine group differences and multivariate associations between variables. The prevalence of depression and anxiety symptoms within this patient population will also be estimated. Phase 2 (pilot RCT) Analyses will follow the intention-to-treat (ITT) principle, in which participants will be analyzed in their originally assigned study arm regardless of protocol adherence, except in cases of formal withdrawal. Patterns of missingness will be examined descriptively by outcome, timepoint, and study arm, and the missing-completely-at-random (MCAR) assumption will be evaluated using Little’s MCAR test. Missingness of approximately 5% or less will be considered acceptable for complete-case analysis [49], provided there is no evidence of systematic missingness. Where missingness exceeds this threshold or appears systematic, sensitivity analyses using multiple imputation or likelihood-based methods will be considered, where appropriate. Primary clinical/process outcome (treatment engagement) Between-group differences in (i) the proportion of participants who express willingness to be referred to mental health services or to schedule a follow-up session immediately post-intervention, and (ii) the proportion who attend the scheduled appointment within 2 weeks, will be examined using chi-square tests or Fisher’s exact tests, where appropriate, with effect sizes (φ or odds ratios with 95% confidence intervals) reported. Exploratory psychosocial (mechanistic) outcomes.1 1 Note: The original analytic plan specified independent-samples t-tests for between-group comparisons of continuous outcomes. Following peer review, these analyses were revised to analysis of covariance (ANCOVA) models adjusting for baseline values of the corresponding outcome measures. This approach was adopted to better account for the repeated-measures nature of the data and to reduce residual variance. This deviation from the pre-registered analytic plan is acknowledged as a protocol amendment. Consistent with the pilot nature of the trial, all revised analyses should be interpreted as exploratory. Continuous psychosocial outcomes (e.g., hope, perceived agency, readiness for change, life satisfaction) will be examined using analysis of covariance (ANCOVA) models comparing groups at post-intervention and at 2-week follow-up while adjusting for baseline values of the corresponding outcome. ANCOVA was selected over linear mixed-effects models given the small pilot sample and the focus on estimating between-group differences at each post-baseline timepoint to inform a future definitive trial. Effect estimates will be accompanied by 95% confidence intervals and standardized effect sizes (e.g., Cohen’s d, partial η2). Given the pilot nature of the trial, analyses will be interpreted as exploratory. Feasibility and acceptability The feasibility of the SF-SSC will be evaluated based on intervention completion rates, defined as the proportion of sessions in which action plans are completed. Feasibility will be considered achieved if at least 70% of sessions result in completed action plans. Interventionists’ qualitative feedback regarding intervention delivery, implementation barriers, and reasons for non-completion will also be collected to further inform feasibility. The acceptability of the SF-SSC will be assessed using participants’ post-intervention ratings of perceived helpfulness in addressing their concerns. Acceptability will be considered achieved if the mean helpfulness rating across participants is 3.0 or higher, indicating that the intervention was perceived as at least “somewhat helpful” in addressing their concerns. Qualitative feedback from participants and interventionists will additionally be analyzed using thematic content analysis to inform intervention refinement. Coding will be conducted independently by at least two members of the research team, with disagreements resolved through discussion or consultation with a third reviewer where necessary. Fidelity Fidelity will be assessed using the observer-rated fidelity checklist. Between group differences in the sum of the even-numbered SFBT-specific items will be examined using independent t-tests, with effect sizes (Cohen’s d, 95% confidence intervals) reported. We expect the SF-SSC condition to demonstrate greater adherence to solution-focused principles than the SPT condition. Ethics and dissemination The study was approved by the Nanyang Technological University Institutional Review Board (IRB-2024-777). Written informed consent will be obtained from all participants. Study status The study is expected to be conducted over a 2-year period. Participant recruitment began in March 2025 and data collection is anticipated to conclude by December 2026. Findings will be disseminated through presentations at national and international conferences and through publications in peer-reviewed journals. Summary This study protocol outlines a two-phase investigation examining: (1) the prevalence of mental health symptoms, service utilization patterns, and psychosocial determinants of treatment engagement among individuals with chronic physical diseases; and (2) the feasibility and acceptability of a Solution-Focused Single-Session Consultation (SF-SSC) as an approach to improving treatment engagement among community health outpatients with comorbid chronic physical diseases and mental health problems (CPDMHP). The goal of the study is to advance our understanding of mental health comorbidities within chronic disease populations in Singapore and to identify scalable approaches for enhancing mental health service engagement. As a treatment engagement approach, the SF-SSC’s brief, manualized structure, and minimal specialized training requirements make it practical for integration into existing healthcare systems [24, 50]. If demonstrated to be feasible and acceptable, the intervention may facilitate earlier and improved engagement with mental healthcare services among individuals with chronic disease, thus helping to mitigate the broader physical and psychological burdens associated with delayed or inadequate care [51]. The SF-SSC also aligns with ongoing efforts to integrate mental healthcare into routine chronic disease management. As healthcare systems increasingly adopt tiered mental health service models, low-intensity, scalable interventions such as the SF-SSC can serve as accessible entry points or adjunctive supports that strengthen patients’ uptake of and engagement with mental health services. Anticipated challenges and limitations One key challenge will be recruiting participants from an outpatient community health setting. Patients undergoing current treatment may feel overwhelmed by their health conditions or perceive study participation to be an additional burden, reducing their willingness to engage with the research team [52]. Adherence to survey completion and follow-up assessments may also be difficult due to symptom burden, competing demands, and limited mental health literacy. To support retention, the study will allow for flexible scheduling options, reminder messages, and incentives, as well as the option for participants to pause or break as needed during data collection [53]. Several additional limitations should be acknowledged. First, generalizability may be limited as recruitment is expected to occur within a single community health organization in Singapore that primarily serves patients with kidney-related conditions. The findings may therefore be less applicable to individuals experiencing other chronic diseases or those receiving care in different healthcare settings. Future studies may benefit from recruiting across multiple health institutions and including a broader range of chronic disease populations to improve external validity. Second, Phase 2 recruitment is restricted to participants who express interest in a “brief consultation session,” which may introduce a self-selection bias. The sample may therefore overrepresent individuals who are more open to receiving support or motivated to engage with intervention, potentially inflating estimates of feasibility, acceptability, and engagement relative to the broader CPDMHP population. Findings should therefore be interpreted as preliminary, and future studies should examine the intervention using broader recruitment strategies that reduce reliance on participant-initiated interest. Third, the 2-week follow-up period was selected to capture proximal indicators of engagement following a brief, single-session intervention intended to facilitate immediate next steps toward help-seeking, and is consistent with the follow-up window adopted in prior SF-SSC trials [24, 25]. Although appropriate for assessing early engagement signals while minimizing participant burden, this timeframe may be insufficient to evaluate sustained service utilization or longer-term outcomes. Future fully powered trials with extended follow-up periods will therefore be needed to determine whether early engagement translates into durable participation in care. Fourth, although the SF-SSC is designed to be delivered by providers with varying levels of clinical training, some variability in intervention delivery is expected. While this may improve real-world applicability, it may also contribute to differences in intervention effects across providers. To minimize this variability, interventionists will receive standardized training, competency review, fidelity monitoring, and regular supervision. Future research will be needed to determine the level of training and supervision required to support consistent implementation at scale. Fifth, the presence of an in-room observer for fidelity assessment may have introduced reactivity effects among both participants (e.g., reduced disclosure of sensitive information or social desirability bias) and interventionists (e.g., closer adherence to protocol than would occur in routine practice). Although observer involvement during sessions will be minimized and informed consent procedures will address the observer’s role, these factors may still limit ecological validity. Finally, as noted in the “Methods and analysis” section, the trial was retrospectively registered. Although the core study design was specified prior to data collection, retrospective registration may reduce transparency regarding pre-specified analyses. In addition, the planned analyses for continuous outcomes were revised from independent-samples t-tests to analysis of covariance (ANCOVA) models following peer review. Although this modification strengthens the methodological rigor of the analyses, it constitutes a post-registration deviation from the original analytic plan. Accordingly, findings related to clinical and psychosocial outcomes should be interpreted with appropriate caution. Future directions Beyond feasibility and acceptability, future research may examine the intervention’s effectiveness at scale and its potential long-term impact using a full randomized controlled trial design. Additional work could also investigate facilitators and barriers to implementation at the organizational, provider, and system levels to inform strategies for broader adoption. Sustainability, cost-effectiveness, and the feasibility of digital or hybrid delivery formats represent further important avenues for future investigation. Supplementary Information Supplementary Material 1. SPIRIT 2025 checklist of items to address in a randomized trial protocol*. Supplementary Material 2. Fidelity Checklist. Supplementary Material 3. Action Plan (for client and therapist). Acknowledgements Not applicable. Authors’ contributions JLT conceptualized the study, developed the methodology, conducted the investigation, secured funding, managed resources, oversaw project administration and supervision, and drafted and revised the original manuscript. JXC conducted the investigation, oversaw project administration and data curation, and drafted the original manuscript. SI drafted and revised the original manuscript. BK provided resources and secured funding. KG provided supervision. SA and LK secured funding. JLS contributed to methodological development, provided resources, and secured funding. Funding This work was supported by NMRC Population Health Research Grant New Investigator Grant [MOH-001428] awarded to JLT, BK, SA, LK, and JLS. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The study was approved by the Nanyang Technological University Institutional Review Board (IRB-2024-777). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. SPIRIT 2025 checklist of items to address in a randomized trial protocol*. Supplementary Material 2. Fidelity Checklist. Supplementary Material 3. Action Plan (for client and therapist). Data Availability Statement No datasets were generated or analysed during the current study.